Photo: the logo of the Boai NKY Medical Holdings Ltd.
BEIJING, Aug. 2 (Xinhua) -- Boai NKY Medical Holdings Ltd. (300109.SZ) announced on Monday that its subsidiary Boai NKY Biotech Co., Ltd will sell a 100-percent stake in NKY Biotech US, Inc. in cash to Abcam US Group Holdings Inc.
According to a filing to the stock exchange, the transaction value is estimated at 343 million U.S. dollars.
NKY Biotech US is a special purpose company established by the listed company in Delaware, USA, and it holds a 100-percent stake in BioVision which is a life science company headquartered in the San Francisco Bay area. After the transaction, the Shenzhen-listed company will no longer hold any equity interest in BioVision.
Headquartered in central China's Henan Province, Boai NKY Medical Holdings Ltd is a high-tech specialty chemical company focused on the development and manufacture of biomaterials. (Edited by Hu Pingchao, Wang Siyi, hupingchao@xinhua.org)
A single purchase
